The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BREAKWATER phase 3: Post hoc subgroup analyses by age in patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Abbvie; Agenus; Amgen (I); Boehringer Ingelheim; Bristol Myers Squibb Foundation; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; Merck; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Johnson & Johnson/Janssen; Larkspur Biosciences Inc; Lilly; Marengo Therapeutics; Menarini; Merus; MSD; Novartis; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Syntelios AG; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech, Therapeutics, S.L. (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim de España S.A. (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Enterome BioScience SA (Inst); Exelixis (Inst); Genentech (Inst); Gercor (Inst); GlaxoSmithKline (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); NuCana plc. (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics
 
Harpreet Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; ERYTECH Pharma; EXACT Therapeutics; Incyte; Jazz Pharmaceuticals/zymeworks; Nordicpharma; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical; Taiho Oncology; Takeda
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Bayer; Oncosil
 
Van Morris
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Tiziana Usari
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer; Viatris
 
Khyati Shah
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nana Rezai
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Xiaosong Zhang
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
Patents, Royalties, Other Intellectual Property - Patents in cancer genomics
Travel, Accommodations, Expenses - Pfizer; Pfizer
 
Jeanne Tie
Honoraria - Merck Serono; MSD Oncology
Consulting or Advisory Role - Arcus Biosciences (Inst); BeiGene; Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Haystack Oncology; Illumina; MSD Oncology; Pierre Fabre; Roche; Takeda
Speakers' Bureau - MSD Oncology
Research Funding - Grail (Inst); Haystack Oncology (Inst); Pierre Fabre (Inst)